BSE Live
Oct 03, 16:01Prev. Close
1958.65
Open Price
1946.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 03, 15:56Prev. Close
1959.20
Open Price
1959.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1980.20 (88)
Profit & Loss account of Glenmark Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 6,491.20 | 6,131.14 | 6,096.05 | 7,694.83 | 5,906.97 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 87.91 | |
Revenue From Operations [Net] | 6,491.20 | 6,131.14 | 6,096.05 | 7,694.83 | 5,819.06 | |
Total Operating Revenues | 6,712.63 | 6,304.87 | 6,431.88 | 8,095.50 | 6,115.17 | |
Other Income | 606.79 | 475.61 | 180.42 | 148.24 | 117.28 | |
Total Revenue | 7,319.42 | 6,780.48 | 6,612.31 | 8,243.74 | 6,232.45 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 2,251.98 | 1,585.85 | 2,038.57 | 2,242.01 | 1,792.24 | |
Purchase Of Stock-In Trade | 365.24 | 301.30 | 288.18 | 267.00 | 219.98 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | 48.77 | 471.81 | 51.85 | -83.52 | -73.55 | |
Employee Benefit Expenses | 1,072.33 | 969.98 | 1,021.92 | 914.47 | 766.25 | |
Finance Costs | 256.39 | 223.81 | 190.90 | 152.60 | 36.22 | |
Depreciation And Amortisation Expenses | 138.54 | 106.28 | 118.20 | 104.93 | 99.81 | |
Other Expenses | 1,670.08 | 1,648.45 | 1,683.87 | 1,856.90 | 1,644.97 | |
Total Expenses | 5,803.33 | 5,307.48 | 5,393.48 | 5,454.39 | 4,485.92 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 1,516.09 | 1,473.00 | 1,218.83 | 2,789.35 | 1,746.53 | |
Exceptional Items | 18.55 | 345.19 | 0.00 | -236.45 | 0.00 | |
Profit/Loss Before Tax | 1,534.64 | 1,818.18 | 1,218.83 | 2,552.90 | 1,746.53 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 269.24 | 383.50 | 270.68 | 604.02 | 374.62 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -89.14 | -53.61 | -66.20 | -191.74 | -112.35 | |
Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 180.10 | 329.88 | 204.48 | 412.29 | 262.26 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 1,354.55 | 1,488.30 | 1,014.35 | 2,140.61 | 1,484.27 | |
Profit/Loss From Continuing Operations | 1,354.55 | 1,488.30 | 1,014.35 | 2,140.61 | 1,484.27 | |
Profit/Loss For The Period | 1,354.55 | 1,622.11 | 1,014.35 | 2,140.61 | 1,484.27 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 48.00 | 57.49 | 35.95 | 75.86 | 52.87 | |
Diluted EPS (Rs.) | 48.00 | 57.49 | 35.94 | 75.84 | 52.86 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 386.60 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 1,347.96 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 56.01 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 68.03 | 68.03 | 67.92 | 67.95 | 67.92 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Equity Dividend Rate (%) | 250.00 | 200.00 | 200.00 | 200.00 | 200.00 |
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
03.12.2024
Glenmark Consolidated September 2024 Net Sales at Rs 3,433.80 crore, up 7.06% Y-o-Y
20.11.2024
Glenmark Standalone September 2024 Net Sales at Rs 2,636.10 crore, up 18.03% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015